

INDEX

TITLE.....	PAGE NO.
List of Figures.....	i
List of Tables.....	vi
List of Excipients.....	viii
List of Instruments.....	x
List of Abbreviations.....	xii
CHAPTER 1 INTRODUCTION	1-16
1.1 Background.....	1
1.2 Objective of the Proposed Work.....	10
1.3 Rationale.....	10
1.4 Hypothesis	10
1.5 Research Design and Method	11
1.6 Expected Results	11
1.7 Work Plan.....	11
1.8 References.....	13
CHAPTER 2 LITERATURE REVIEW	17-76
2.1 Pulmonary Hypertension.....	17
2.2 Classification of Pulmonary Hypertension.....	18
2.3 Epidemiology of PAH.....	20
2.4 Pathogenesis.....	21
2.5 Diagnosis	22
2.6 Current Therapy for Treatment of PAH.....	23
2.7 Gene Therapies for Pulmonary Hypertension	25
2.8 Fibroblast Growth Factor 2 (FGF2).....	27
2.9 RNA Interference.....	29
2.9.1 Targets of RNAi.....	30
2.9.2 Cellular Mechanisms of RNAi.....	30
2.10 Small Interfering RNA (siRNA).....	31
2.11 Challenges to RNAi Delivery.....	34
2.11.1 Physiological Barriers.....	34

2.11.2 Cellular Barriers.....	36
2.12 Potential of RNAi as Therapeutics.....	37
2.13 siRNA Delivery: Role of Vectors	40
2.14 Polyethylenimine.....	41
2.14.1 PEI Complexes	44
2.14.2 Polymer Structure Influences Polyplex Characteristics	46
2.14.3 Modification to Achieve Tissue Specificity and Enhance Cellular Uptake	47
2.14.4 Linking Physico-chemistry to Biology	49
2.15 Pulmonary Drug Delivery.....	51
2.15.1 Human Pulmonary System.....	52
2.15.2 Challenges in Pulmonary Delivery of siRNA	53
2.15.3 Delivery Strategies for Pulmonary Delivery of siRNA	54
2.16 References.....	56

CHAPTER 3 siRNA PROFILE AND ANALYTICAL

METHOD DEVELOPMENT.....	77-93
3.1 Bovine FGF-2 siRNA.....	78
3.2 Rat FGF-2 siRNA	81
3.3 UV Spectrophotometric Analysis of siRNA.....	83
3.3.1 Accuracy and Precision of Method.....	85
3.4 siRNA Gel Electrophoresis: Gel Retardation Assay.....	86
3.4.1 Method of Analysis.....	87
3.4.2 Determination of Quantifiable Range of siRNA for Gel Retardation Assay	88
3.4.3 Relative Quantification	89
3.4.4 Accuracy and Precision of the Method.....	90
3.5 References.....	92

CHAPTER 4 POLYMER SYNTHESIS AND CHARACTERIZATION..... 94-121

4.1 Methods	96
4.1.1 Polymer Synthesis.....	96
4.1.2 Fourier Transform Infrared Spectroscopy (FT-IR).....	98
4.1.3 Nuclear Magnetic Resonance (NMR) Spectroscopy	99
4.1.4 TNBS Assay	99

4.1.5 Gel Permeation Chromatography	100
4.1.6 Acid Base Titration	100
4.1.7 Hemolysis Study	101
4.1.8 Erythrocytes Aggregation Assay	101
4.2 Results and Discussion	102
4.2.1 Fourier Transform Infrared Spectroscopy (FTIR).....	102
4.2.2 Nuclear Magnetic Resonance (NMR) Spectroscopy	104
4.2.3 TNBS Assay	106
4.2.4 Gel Permeation Chromatography	108
4.2.5 Acid Base Titration	110
4.2.6 Hemolytic Potential and Erythrocyte Aggregation Study.....	112
4.3 References.....	119

CHAPTER 5 FORMULATION DEVELOPMENT AND

CHARACTERIZATION..... 122-193

5.1 Methods	123
5.1.1 Preparation of siRNA Nanoplexes.....	123
5.1.1.1 Preparation of Polyplexes	123
5.1.1.2 Preparation of Lipoplexes	123
5.1.2 Complexation Efficiency.....	124
5.1.2.1 Gel Retardation Assay	124
5.1.2.2 Centrifugation	124
5.1.3 Determination of siRNA Integrity	124
5.1.4 Particle Size and Zeta Potential	125
5.1.5 Cell-line Studies.....	125
5.1.5.1 Sub Culturing Protocol for CPA-47 Cell Line.....	125
5.1.5.2 Cell Counting Using Haemocytometer.....	126
5.1.5.3 <i>In vitro</i> Cytotoxicity Assay	127
5.1.5.4 <i>In vitro</i> Cell Uptake Studies.....	129
5.1.5.5 <i>In vitro</i> Gene Expression Studies by Real Time PCR.....	132
5.1.5.6 <i>In vitro</i> Cell Line Studies of Optimized Formulation at Low Oxygen Tension	136
5.1.6 Heparin Polyanion Competition Assay.....	137

5.1.7 Serum Stability Study	138
5.1.8 Salt Induced Aggregation Study	140
5.1.9 Stability Study in Bronchoalveolar Lavage Fluid	140
5.1.10 Transmission Electron Microscopy	142
5.2 Results and Discussion	142
5.2.1 siRNA Complexation	142
5.2.2 Particle Size and Zeta Potential	149
5.2.3 <i>In vitro</i> Cell Cytotoxicity Study	153
5.2.4 <i>In vitro</i> Cell Uptake Studies by Confocal Microscopy	156
5.2.5 <i>In vitro</i> Cell Uptake Studies by Flow Cytometry	161
5.1.5.6 <i>In vitro</i> Gene Expression Study by Real Time PCR	166
5.2.7 <i>In vitro</i> Cell Line Studies in HCPA-47 Cells	169
5.2.7.1 <i>In vitro</i> Cytotoxicity Study	169
5.2.7.2 <i>In vitro</i> Cellular Uptake Studies	169
5.2.7.3 <i>In vitro</i> Gene Expression Study by RT-PCR	175
5.2.8 Heparin Polyanion Competition Assay	177
5.2.9 Serum Stability Study	179
5.2.10 Salt Induced Aggregation Study	181
5.2.11 Stability Study in Bronchoalveolar Lavage Fluid	183
5.2.12 Transmission Electron Microscopy	185
5.3 References	187

CHAPTER 6 DEVELOPMENT OF DRY POWDERS FOR INHALATION 194-212

6.1 Methods	195
6.1.1 Cryo Differential Scanning Calorimetric (Cryo-DSC) Studies	195
6.1.2 Lyophilization of Nanoplexes	195
6.1.3 Residual Water Content	197
6.1.4 Particle Size and Zeta Potential:	198
6.1.5 Aerosolization Performance of the Formulations	198
6.1.5.1 Spectrofluorometric Method for Detection of Rhodamine	198
6.1.5.2 Aerodynamic Particle Size using Andersen Cascade Impactor (ACI)	198
6.1.6 Integrity of siRNA	200
6.1.7 X-ray Diffraction Studies	200

6.2 Results and Discussion.....	200
6.2.1 Cryo DSC	200
6.2.2 Lyophilization of Nanoplexes	203
6.2.3 Particle Size, Zeta Potential and Moisture Content	204
6.2.4 Spectrofluorometric Method for Detection of Rhodamine B.....	206
6.2.5 Aerosolization Performance of Dry Powder for Inhalation	208
6.2.6 X-ray Diffraction Studies	209
6.3 References.....	211

CHAPTER 7 ANIMAL STUDIES 213-231

7.1 Methods	213
7.1.1 Selection of Animals Species	213
7.1.2 Housing and Feeding Conditions.....	214
7.1.3 Preparation of Animals	214
7.1.4 Monocrotaline (MCT) Administration.....	214
7.1.5 Effects of Pulmonary Delivery of FGF2 siRNA Dry Powder Formulations in MCT-induced Pulmonary Hypertensive Rats	214
7.1.6 Study Parameters	215
7.1.6.1 Hemodynamic Measurements.....	216
7.1.6.2 Effect on FGF2 mRNA Level in Lung Homogenate	216
7.1.6.3 Right Ventricular Hypertrophy Measurement	217
7.1.6.4 Histopathology	217
7.1.7 Acute toxicity study	218
7.1.7.1 Preparation of Doses.....	218
7.1.7.2 Administration of Doses	218
7.1.7.3 Numbers of Animals and Dose Levels	218
7.1.7.4 Clinical Observations	219
7.1.7.5 Bronchoalveolar Fluid Examination.....	219
7.1.7.6 Histopathological Examination of Lung.....	220
7.2 Results and Discussion.....	220
7.2.1 Treatment in MCT Administered Rats.....	220
7.2.2 Acute Toxicity Studies.....	226

7.3 References..... 230

CHAPTER 8 STABILITY STUDIES 232-239

8.1 Method..... 232

8.2 Results 233

8.3 References..... 237

CHAPTER 9 SUMMARY AND CONCLUSIONS..... 240-248

List of Figures

Figure 1.1 Pathophysiology of progression of PAH.	2
Figure 1.2 Role of vascular remodeling in the progression of PAH.	3
Figure 1.3 Mechanism of action of siRNA therapy.	7
Figure 2.1 Pathogenesis of pulmonary hypertension.	17
Figure 2.2 Distribution of patients with PAH in the 2002 to 2003 French Registry.	20
Figure 2.3 Potential targets for treatment of pulmonary hypertension.	22
Figure 2.4 Cellular mechanism of RNAi.	31
Figure 2.5 Basic structure of siRNA.	32
Figure 2.6 Mechanism of siRNA.	33
Figure 2.7 Various extracellular and intracellular barriers for siRNA.	34
Figure 2.8 Acid-catalyzed polymerization of aziridine leads to branched PEI, whereas ring opening polymerization of 2-ethyl-2-oxazoline leads to the N -substituted polymer, which can be transformed via hydrolysis into linear PEI.	43
Figure 2.9 Anatomy and physiology of pulmonary system.	52
Figure 3.1 MALDI-Mass spectrometry of sense strand of Bovine siRNA.	79
Figure 3.2 Capillary Gel Electrophoresis (CGE) analysis of sense strand of Bovine siRNA.	79
Figure 3.3 MALDI-Mass spectrometry of antisense strand of Bovine siRNA.	80
Figure 3.4 Capillary Gel Electrophoresis (CGE) analysis of antisense strand of Bovine siRNA.	80
Figure 3.5 MALDI-Mass spectrometry of sense strand of Rat siRNA.	81
Figure 3.6 Capillary Gel Electrophoresis (CGE) analysis of sense strand of Rat siRNA.	82
Figure 3.7 MALDI-Mass spectrometry of antisense strand of Rat siRNA.	82
Figure 3.8 Capillary Gel Electrophoresis (CGE) analysis of antisense strand of Rat siRNA.	83
Figure 3.9 Results generated from NanoDrop.	84
Figure 3.10 Correlation of actual concentration Vs observed concentration of siRNA by NanoDrop.	85
Figure 3.11 Agarose gel.	87
Figure 3.12 Estimation of minimum quantity of siRNA by gel retardation assay.	88
Figure 3.13 Determination of quantifiable range of siRNA - gel electrophoresis band	

densities at different siRNA concentrations.	88
Figure 3.14 Gel electrophoresis band densities at different siRNA concentrations.	89
Figure 3.15 Calibration plot of siRNA gel retardation.....	90
Figure 3.16 Accuracy and precision of gel electrophoresis for siRNA quantification.	91
Figure 3.17 Detection of molecular weight of siRNA in comparison to DNA ladder.	91
Figure 4.1 Structure of polyethylenimine (PEI).	97
Figure 4.2 Structure of Boc-alanine modified PEI	97
Figure 4.3 Structure of Boc-leucine modified PEI.	98
Figure 4.4 Structure of Boc-histidine modified PEI.	98
Figure 4.5 IR spectra of PEI.	102
Figure 4.6 IR spectra of Boc-alanine modified PEI.....	103
Figure 4.7 IR spectra of Boc-histidine modified PEI.....	103
Figure 4.8 IR spectra of Boc-leucine modified PEI.....	104
Figure 4.9 ¹ HNMR spectrum of Boc-alanine modified PEI.....	105
Figure 4.10 ¹ HNMR spectrum of Boc-histidine modified PEI.....	105
Figure 4.11 ¹ HNMR spectrum of Boc-leucine modified PEI.....	106
Figure 4.12 UV spectra of TNBS assay for determination of primary amine in PEI.	107
Figure 4.13 Calibration curve for determination of primary amine in PEI.....	107
Figure 4.14 Chromatograph for calibration curve of gel permeation chromatography.	108
Figure 4.15 Calibration curve of gel permeation chromatography.....	109
Figure 4.16 Acid base titration curves for different polymers.	111
Figure 4.17 Hemolytic potential of different modified PEIs at different concentrations.	113
Figure 4.18 Erythrocyte aggregation by negative control.....	113
Figure 4.19 Erythrocyte aggregation by PEI.	114
Figure 4.20 Erythrocyte aggregation by AA.	114
Figure 4.21 Erythrocyte aggregation by BA.	114
Figure 4.22 Erythrocyte aggregation by CA.	115
Figure 4.23 Erythrocyte aggregation by AH.	115
Figure 4.24 Erythrocyte aggregation by BH.	115
Figure 4.25 Erythrocyte aggregation by CH.	116
Figure 4.26 Erythrocyte aggregation by AL.....	116
Figure 4.27 Erythrocyte aggregation by BL.....	116

Figure 4.28 Erythrocyte aggregation by CL.....	117
Figure 5.1 Haemocytometer diagram for cellcounting.....	126
Figure 5.2 Reagents for cell viability assessment.....	128
Figure 5.3 Gel retardation assay of PP.....	143
Figure 5.4 Gel retardation assay of (A) ALP, (B) BLP and (C) CLP.....	144
Figure 5.5 Gel retardation assay of (A) AAP, (B) BAP and (C) CAP.....	145
Figure 5.6 Gel retardation assay of (A) AHP, (B) BHP and (C) CHP.....	146
Figure 5.7 Gel retardation assay of DL.....	147
Figure 5.8 Integrity of siRNA after complexation with polymers.....	148
Figure 5.9 Integrity of siRNA after complexation with polymers/lipids.....	149
Figure 5.10 Particle sizes of different nanoplexes.....	151
Figure 5.11 Cytotoxicity of AAP, BAP and CAP.....	153
Figure 5.12 Cytotoxicity of AHP, BHP and CHP.....	154
Figure 5.13 Cytotoxicity of ALP, BLP and CLP.....	154
Figure 5.14 Cellular uptake of naked FAM-NC-siRNA and PP by confocal microscopy.....	157
Figure 5.15 Cellular uptake of CAP, BAP and AAP by confocal microscopy.....	157
Figure 5.16 Cellular uptake of CHP, BHP and AHP by confocal microscopy.....	158
Figure 5.17 Cellular uptake of CLP, BLP and ALP by confocal microscopy.....	159
Figure 5.19 2D histograms (A) and dot plots (B) of cell uptake for naked siRNA and PP by FACS.....	161
Figure 5.20 2D histograms (A) and dot plots (B) of cell uptake for CAP, BAP and AAP by FACS.....	162
Figure 5.21 2D histograms (A) and Dot plots (B) of cell uptake for CHP, BHP and AHP by FACS.....	162
Figure 5.22 2D histograms (A) and dot plots (B) of cell uptake for CLP, BLP and ALP by FACS.....	163
Figure 5.23 2D histograms (A) and dot plots (B) of cell uptake for DL and L2KL by FACS. ..	163
Figure 5.24 %Mean fluorescence intensity in CPA-47 cells by FACS.....	166
Figure 5.25 Gene expression study of different formulations in CPA-47 cells.....	167
Figure 5.26 Cytotoxicity of nanoplexes in HCPA-47 cells.....	169
Figure 5.27 Cell uptake of screened formulations in HCPA-47 cells by confocal microscopy..	171

Figure 5.28 2D histograms (A) and dot plots (B) of cell uptake for PP, AAP, AHP and ALP in HCPA-47 cells by FACS.....	172
Figure 5.29 2D histograms (A) and dot plots (B) of cell uptake for DL and L2KL in HCPA-47 cells by FACS.	173
Figure 5.30 Cell uptake of screened formulations in HCPA-47 cells by confocal microscopy..	174
Figure 5.31 % Gene expression in HCPA-47 cells after treatment with various formulations...	175
Figure 5.32 Heparin polyanion competition assay A) AAP; B) ALP; C)AHP and D) DL.	178
Figure 5.33 Serum stability of nanoplexes as compared to naked siRNA.	180
Figure 5.34 Electrolyte induced flocculation of nanoplexes.	183
Figure 5.35 siRNA retained in nanoplexes after incubation with BALF.....	184
Figure 5.36 Cryo-TEM image of DL.	185
Figure 5.37 TEM images of AAP (A), AHP (B) and ALP (C).	186
Figure 6.1 Thermal Cycle for Freeze Drying	197
Figure 6.2 DSC thermogram of PEI.....	201
Figure 6.3 DSC thermogram of AA.....	201
Figure 6.4 DSC thermogram of AH.....	202
Figure 6.5 DSC thermogram of AL.	202
Figure 6.6 Thermal graph of freeze drying cycle.	204
Figure 6.7 Spectrofluorometric spectras of Rhodamine B.	206
Figure 6.8 Calibration curve for Rhodamine B	206
Figure 6.9 Interference study of Rhodamine B with lactose(A), trehalose(B) and sucrose(C)...	207
Figure 6.10 Integrity of siRNA in dry powder formulations.....	209
Figure 6.11 X-Ray Diffractogram of Lactose	210
Figure 6.12 X-Ray Diffractogram of PDPI L1	210
Figure 7.1 Intratracheal administration in rats.....	215
Figure 7.2 Right ventricular systolic pressure in MCT induced pulmonary hypertensive rats after treatment with various formulations.	221
Figure 7.3 Right ventricular hypertrophy (%) in MCT induced pulmonary hypertensive rats after treatment with various formulations.	221
Figure 7.4 Mean systemic arterial pressure in MCT induced pulmonary hypertensive rats after treatment with various formulations.	222

Figure 7.5 Amplification plot of gene expression study by RT-PCR.	222
Figure 7.6 % Gene expression of FGF2 mRNA in MCT induced pulmonary hypertensive rats after treatment with various formulations.	223
Figure 7.7 Histopathology of Positive control (A), Placebo Control (B), Normal Control (C) and treatment with PDPI L3 (D), PDPI L2 (E), PDPI L1 (F) and LDPI (G).....	226
Figure 7.8 Histopathology of lung tissue sample at 5 times higher dose of Control (A), ALP (B), AAP (C), AHP (D) and liposomes (E).....	229
Figure 8.1 siRNA integrity after 3 months stability as compared to 10 bp ladder at 25°C ± 2°C, 60% RH ± 5% RH (A) and 5°C ± 3°C (B).	235

List of Tables

Table 1.1 siRNA therapy in clinical trials.....	9
Table 2.1 Hemodynamic definitions of pulmonary hypertension	18
Table 2.2 Involvement of different genes in pulmonary hypertension	26
Table 2.3 Modes of RNAi delivery and potential targets in various diseases.....	38
Table 2.4 Therapeutic intervention using siRNA	39
Table 2.5 Strategies to overcome barriers with PEI-based gene delivery.....	50
Table 3.1 Results of accuracy measurements.....	86
Table 3.2 Interday and intraday precision of the method.....	86
Table 3.3 Relative band densities at different siRNA concentrations	90
Table 4.1 Nomenclature of synthesized polymers.....	97
Table 4.2 % Primary amine modification in modified PEIs	108
Table 4.3 Retention time of standards of different molecular weight	109
Table 4.4 Molecular weights of modified PEIs.....	110
Table 5.1 Cell line treatment parameters for MTT assay.....	129
Table 5.2 Cell line treatment parameters for confocal microscopy and flow-cytometry.....	131
Table 5.3 Details of primers	135
Table 5.4 RNA to cDNA conversion parameters	135
Table 5.5 Steps of RT- PCR cycle	135
Table 5.6 mRNA quantification – reaction parameters.....	136
Table 5.7 RT-PCR cycle steps.....	136
Table 5.8 Different optimized siRNA formulations	147
Table 5.9 Particle size and zeta potential of nanoplexes.....	150
Table 5.10 Uptake of various formulations in CPA-47 cells	164
Table 5.11 Gene expression study of different formulations in CPA-47 cells.....	167
Table 5.12 Cell uptake of screened formulations in HCPA-47 cells by FACS.....	173
Table 5.13 Gene expression in HCPA-47 cells after treatment with various formulations ..	175
Table 5.14 Serum stability of nanoplexes as compared to naked siRNA	180

Table 5.15 Electrolyte induced flocculation of nanoplexes	182
Table 5.16 Stability of nanoplexes in BAL fluid.....	184
Table 6.1 Optimization of lyophilization for AHP	205
Table 6.2 Lyophilization of AAP, ALP and lipoplex	205
Table 6.3 Results of accuracy measurements.....	207
Table 6.4 Intraday and interday precision of the method.....	207
Table 6.5 Aerodynamic particle size of dry powder formulations.	208
Table 7.1 Primers for RT-PCR	217
Table 7.2 Dosing levels of carriers	219
Table 7.3 Cell counts in bronchoalveolar lavage fluids.....	227
Table 8.1 Stability of PDPI L1	233
Table 8.2 Stability of PDPI L2	234
Table 8.3 Stability of PDPI L3	234
Table 8.4 Stability study of LDPI	235